A Preview Of Teva Pharmaceutical Indus's Earnings
Portfolio Pulse from Benzinga Insights
Teva Pharmaceutical Industries (NYSE:TEVA) is scheduled to release its quarterly earnings report on January 31, 2024. Analysts predict an EPS of $0.76. Investors are looking for an earnings beat and positive guidance for future growth. Historically, TEVA's stock price has been sensitive to earnings performance and guidance. Last quarter, TEVA missed EPS estimates by $0.01, resulting in a 4.15% share price decline. Over the past year, TEVA shares have increased by 11.6%.
January 30, 2024 | 2:01 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Teva Pharmaceutical is expected to report an EPS of $0.76 for the upcoming quarter. Historical data shows that earnings misses can negatively impact the stock price, as seen with a 4.15% drop after last quarter's miss. Shares have risen 11.6% over the past 52 weeks, indicating a positive trend for long-term investors.
The short-term impact on TEVA's stock price will likely hinge on whether the company meets or exceeds the EPS estimate and provides positive guidance. Historical performance suggests that missing estimates can lead to a price drop, but the overall positive trend over the past year may mitigate severe negative reactions. The score is neutral due to the uncertainty of the earnings outcome and the mixed historical price reactions.
CONFIDENCE 80
IMPORTANCE 85
RELEVANCE 100